ALCAM and colorectal carcinoma: Among the 13 prioritized targets, eight (ADAM10, ALCAM, CD58, CD59, ITGAM, SELP, TSPAN9 and TTYH3) were previously reported to be dysregulated in tissue and/or plasma specimens from CRC patients [69,70,71,72,73,74,75,76].